Anew Medical, Inc.

Strategic Rebranding Reflects Focus on Neurodegenerative Therapies and Healthy LongevityNEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ: KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will have no impact on current shareholders, and there is no action required on their part. The new name embodies the Company's commitment to strategically direct its core investments of time and financial resources toward the multibillion-dollar market opportunities for the company’s patented Klotho gene technology assets in the neurosciences sector. Through its exclusive worldwide license, the company’s patent protected secreted form of the Klotho gene, s-KL, provides Klotho Neurosciences with the opportunity to invest its strategic resources into two distinct major market segments. Innovative Prescription Drugs for Neurodegenerative Diseases The first is the development of new and highly innovative prescription drugs for the treatment of neurodegenerative diseases and age related disorders. From this point forward, Klotho Neurosciences will focus significant attention on the development of its lead candidate, a novel treatment for Amyotrophic Lateral Sclerosis (ALS - also known as Lou Gehrig’s disease), where the company hopes to expeditiously gain FDA approval to enter the clinic. The other key neurological areas of strategic focus for the company are the development of novel therapeutics to treat Alzheimer’s and Parkinson’s disease utilizing the company’s proprietary s-KL gene therapy platform. In these indication areas, and other age-related disorders, the company foresees the potential of entering into research collaborations and partnership agreements with major pharmaceutical companies that are strategically investing in these specific areas. Healthy Longevity The second is the potential to increase healthy longevity or lifespan using the company’s patented s-KL. In pursuit of this, Klotho Neurosciences has entered into an important collaboration with the “Blue Zone” researchers at the Okinawa Research Center for Longevity Science (ORCLS) based in Japan and Hawaii. These researchers have been studying Centenarians and healthy long life spans for many years, and have collected and stored blood samples from these healthy long living individuals. By analyzing these samples, the company anticipates that it will be possible to determine s-KL and Klotho blood and tissue levels in these healthy, long-living persons. Based on preliminary data, the company anticipates that the data will confirm that Klotho protein expression is normalized (not depleted) in these people with long life spans as compared to age-matched control groups. This work will also enable Klotho Neurosciences to validate the clinical assays that are needed for this study which, in the future, may be used to identify persons at high risk for the development of ‘accelerated aging’ and neurologic pathologies. The benefit of this would be that physicians would be able to intercede more promptly in an intervention to provide treatments for these neurologic pathologies prior to persons presenting with advanced disease. Dr. Joseph Sinkule, Chairman, CEO, and Founder commented: “Our new name truly reflects our strategic area of focus going forward. We are excited in particular about the potential of developing novel therapeutics to treat the devastating neurodegenerative disorders such as ALS. Alzheimer’s and Parkinson’s disease, based on our patented secreted form of the Klotho gene, s-KL. The Klotho gene is referred to as the ‘anti-aging gene’ because studies have shown that over-expression of the gene results in improved cognition and a prolonged life span, whereas, conversely, an absence of the gene and gene transcript causes rapid death from age-related pathologies.” Dr. Shalom Hirschman, the company’s Chief Medical Advisor, added: “The data in a severe animal model of human ALS is very compelling. Our plan is to meet with the FDA as soon as possible to discuss the IND and propose a timetable for the potential commencement of clinical trials in ALS patients.” About Klotho Neurosciences, Inc.Klotho Neurosciences, Inc. formerly ANEW MEDICAL, INC., is a Nasdaq-listed pharmaceutical company with the ticker symbol KLTO. The company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer’s and Parkinson’s disease, multiple sclerosis, and rare neurodegenerative diseases. The company is managed by a team of individuals and advisors that are highly experienced in medical product development and commercialization of medical products. For additional information, please visit www.klothoneuro.com. For more information, contact:Eric Boyd, Investor RelationsEmail: IR@klothoneuro.com Website: www.klothoneuro.com Forward-Looking Statements:This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Company will use novel, patented Klotho Gene (s-KL) in studiesNEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer’s and Parkinson’s disease. ANEW has secured exclusive worldwide rights and issued patents in the USA, Canada, Europe, Hong Kong and China, covering the secreted form of Klotho, known scientifically as s-KL. Klotho is often referred to as “the anti-aging gene.” It is named after the Greek goddess who is said to spin the thread of life. Existing data supports ANEW’s scientific hypothesis that maintaining high levels of Klotho as we age leads to a long and healthy life (often into the 100s) whereas depleted levels of Klotho may lead to neurodegenerative diseases such as ALS, Alzheimer’s and Parkinson’s Diseases as well as other age-related disorders including cardiovascular conditions, osteoporosis, and the muscle-wasting disorder, sarcopenia. ANEW hopes to further demonstrate the validity of its hypothesis by examining the stored blood samples of a cohort of people who stayed healthy and reached very old age, many in excess of 100 years, in Okinawa, Japan. Okinawa is one of the famous “Blue Zones” of the world (see the Netflix documentary series “Living to 100”). The results of this study will be compared to a matching cohort of an aging population who have experienced neurodegenerative diseases such as ALS, Alzheimer’s, Parkinson’s and other age-related disorders. ANEW is focused on both enhancing the potential for people to experience healthy longevity as well as on the development of cell and gene-based therapies to treat neurodegenerative and age-related disorders based on its patented Klotho technology. The company hopes to obtain FDA agreement in the near future to enter the clinic in at least one indication area. It has also recently announced a partnership with the key scientists involved in the Okinawa Centenarian Research Center for Longevity who are retained as Advisor on longevity and the development of new pharmaceutical treatments. This includes Drs. Craig and Bradley Willcox, authors of the best-selling, Oprah Winfrey recommended, book, “The Okinawa Program: How the World’s Longest-Lived People Achieve Everlasting Health-And How You Can Too.” Commenting on this development, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW, stated: “Our recent Nasdaq listing will provide us with the opportunity to more expeditiously pursue our development programs to produce cell and gene therapies based on our proprietary Klotho technology. Also, having Drs. Michio Shimabukuro, Richard Allsopp, and Craig and Bradley Willcox of the Okinawa Centenarian Research Center for Longevity Sciences as retained Advisors to our company will be highly important in guiding our development based on their scientific insights in the field of longevity and the data contained in the stored blood samples of Okinawa centenarians.” About ANEW MEDICAL, INC.ANEW MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer’s and Parkinson’s disease, multiple sclerosis and rare neurodegenerative disorders. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, contact:Eric BoydInvestor RelationsEmail: IR@anewmeds.com Forward-Looking Statements:This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Successful Conversion Eliminates Over $4 Million in Long-Term DebtNEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in long-term debt not only clears ANEW’s balance sheet but also significantly increases stockholder equity, positioning the company for future growth and investment opportunities. It also eliminates $600,000 in annual interest payments owed by the company. The average conversion price was approximately $1.08 per share, echoing investors’ long-term commitment to the Company. “This debt conversion reflects the strong confidence our investors have in ANEW’s growth potential and strategic direction,” said Jeffrey LeBlanc, ANEW’s Chief Financial Officer. “By emerging long-term debt-free, we gain significant financial flexibility, which allows us to invest more aggressively in our cutting-edge research and development.” With a solid financial foundation, ANEW is well-positioned to advance its innovative research pipeline targeting the growing market of age-related diseases. The company remains committed to delivering transformative therapies that improve quality of life for aging populations worldwide. About ANEW MEDICAL, INC. ANEW MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as Alzheimer’s and Parkinson’s Disease, ALS, multiple sclerosis and rare neurodegenerative diseases. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, contact:Investor RelationsEmail: IR@anewmeds.com Website: https://www.anewmeds.com/press-releases/ Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.